Hua Medicine

OverviewSuggest Edit

Hua Medicine is a clinical-stage drug development company. It focuses on novel therapies for the treatment of diabetes and CNS disorders. The company provides an oral drug for the treatment of Type 2 Diabetes into NDA enabling stage and started 2 Phase 3 trials in China for drug-naive and metformin-treated T2D patients. In addition, it develops an internal research quality supervision system Q (QC/QA) based on the advanced open innovation model VIC (VC + IP + CRO).
TypePrivate
Founded2010
HQShanghai, CN
Websitehuamedicine.com

Latest Updates

Employees (est.) (Nov 2019)44(+3%)

Key People/Management at Hua Medicine

Li Chen

Li Chen

President and CEO

Hua Medicine Office Locations

Hua Medicine has offices in Shanghai and Wuhan Shi
Wuhan Shi, CN
1 Zhongshan Ave, Qiaokou Qu
Show all (4)

Hua Medicine Financials and Metrics

Summary Metrics

Hua Medicine's latest funding round in March 2018 was reported to be $117.4 m. In total, Hua Medicine has raised $242.4 m
Show all financial metrics

Hua Medicine Online and Social Media Presence

Embed Graph

Hua Medicine News and Updates

Hua Medicine to Release Phase III 24-Weeks Topline Data of Dorzagliatin Monotherapy Trial (HMM0301) on November 12

SHANGHAI, China, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of type 2 diabetes, today announced that 24-week topline data of dorzagliatin’s monotherapy trial (HMM03…

Hua Medicine – Business & Pipeline Update

SHANGHAI, China, June 04, 2019 (GLOBE NEWSWIRE) -- Hua Medicine (HKEX: 2552), announced today our updated pipeline regarding our core technology targeting glucose homeostasis and first product, a glucokinase activator dorzagliatin (HMS5552).

Hua Medicine Initiates First Combination Study of Dorzagliatin with SGLT-2 in the United States

SHANGHAI, China, April 22, 2019 (GLOBE NEWSWIRE) -- Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, announced today dosing of the first patient in a Phase I drug-drug interaction tria…

Hua Medicine Initiates First Combination Study of Dorzagliatin with a DPP-4 Inhibitor in the United States

SHANGHAI, China, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Hua Medicine (“Hua” or “the Company”; Stock Code: 2552.HK) a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes (T2D), announced today dosing of the first patient in…

MOVES-China's Hua Medicine appoints BAML banker as new CFO ahead of listing

HONG KONG, Dec 22 (Reuters) - Chinese drug developer Hua Medicine has appointed George Lin, a veteran Bank of America Merrill Lynch banker as its chief financial officer, as it seeks to go public in the next 12 to 18 months.

Hua Medicine Frequently Asked Questions

  • When was Hua Medicine founded?

    Hua Medicine was founded in 2010.

  • Who are Hua Medicine key executives?

    Hua Medicine's key executives are Li Chen.

  • How many employees does Hua Medicine have?

    Hua Medicine has 44 employees.

  • Who are Hua Medicine competitors?

    Competitors of Hua Medicine include Ergomed, AEterna Zentaris and Evotec.

  • Where are Hua Medicine offices?

    Hua Medicine has offices in Shanghai and Wuhan Shi.

  • How many offices does Hua Medicine have?

    Hua Medicine has 4 offices.